Fallopian Tube Cancer - Pipeline Review, H1 2018

Publisher Name :
Date: 24-Apr-2018
No. of pages: 950
Inquire Before Buying

Fallopian Tube Cancer - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Pipeline Review, H1 2018, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.

Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients.

Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 13, 61, 41, 9, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 7 molecules, respectively.

Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Fallopian Tube Cancer - Pipeline Review, H1 2018

Table of Contents
Table of Contents 2
Introduction 6
Fallopian Tube Cancer - Overview 7
Fallopian Tube Cancer - Therapeutics Development 8
Fallopian Tube Cancer - Therapeutics Assessment 25
Fallopian Tube Cancer - Companies Involved in Therapeutics Development 41
Fallopian Tube Cancer - Drug Profiles 80
Fallopian Tube Cancer - Dormant Projects 920
Fallopian Tube Cancer - Discontinued Products 923
Fallopian Tube Cancer - Product Development Milestones 924
Appendix 935

List of Tables
Number of Products under Development for Fallopian Tube Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Fallopian Tube Cancer - Pipeline by AbbVie Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
Fallopian Tube Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018
Fallopian Tube Cancer - Pipeline by Altor BioScience Corp, H1 2018
Fallopian Tube Cancer - Pipeline by Amgen Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2018
Fallopian Tube Cancer - Pipeline by Astellas Pharma Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2018
Fallopian Tube Cancer - Pipeline by AstraZeneca Plc, H1 2018
Fallopian Tube Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Bayer AG, H1 2018
Fallopian Tube Cancer - Pipeline by BeiGene Ltd, H1 2018
Fallopian Tube Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Fallopian Tube Cancer - Pipeline by Boston Biomedical Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018
Fallopian Tube Cancer - Pipeline by Caladrius Biosciences Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Celgene Corp, H1 2018
Fallopian Tube Cancer - Pipeline by Celldex Therapeutics Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Celsion Corp, H1 2018
Fallopian Tube Cancer - Pipeline by Celyad SA, H1 2018
Fallopian Tube Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2018
Fallopian Tube Cancer - Pipeline by Eisai Co Ltd, H1 2018
Fallopian Tube Cancer - Pipeline by Eli Lilly and Co, H1 2018
Fallopian Tube Cancer - Pipeline by EpiThany Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Exelixis Inc, H1 2018
Fallopian Tube Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Fallopian Tube Cancer - Pipeline by Fate Therapeutics Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Gene Techno Science Co Ltd, H1 2018
Fallopian Tube Cancer - Pipeline by Genentech Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Genor BioPharma Co Ltd, H1 2018
Fallopian Tube Cancer - Pipeline by GlaxoSmithKline Plc, H1 2018
Fallopian Tube Cancer - Pipeline by Glycotope GmbH, H1 2018
Fallopian Tube Cancer - Pipeline by Gradalis Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Ignyta Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Immune Design Corp, H1 2018
Fallopian Tube Cancer - Pipeline by ImmunoGen Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Immunovaccine Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Innate Pharma SA, H1 2018
Fallopian Tube Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Fallopian Tube Cancer - Pipeline by Johnson & Johnson, H1 2018
Fallopian Tube Cancer - Pipeline by Juno Therapeutics Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Kazia Therapeutics Ltd, H1 2018
Fallopian Tube Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H1 2018
Fallopian Tube Cancer - Pipeline by MedImmune LLC, H1 2018
Fallopian Tube Cancer - Pipeline by Merck & Co Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Merck KGaA, H1 2018
Fallopian Tube Cancer - Pipeline by Mersana Therapeutics Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Fallopian Tube Cancer - Pipeline by MolMed SpA, H1 2018
Fallopian Tube Cancer - Pipeline by Mycenax Biotech Inc, H1 2018
Fallopian Tube Cancer - Pipeline by NewLink Genetics Corp, H1 2018
Fallopian Tube Cancer - Pipeline by Novartis AG, H1 2018
Fallopian Tube Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2018
Fallopian Tube Cancer - Pipeline by OBI Pharma Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Omnitura Therapeutics Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Oncobiologics Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Oncolix Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Oncolytics Biotech Inc, H1 2018
Fallopian Tube Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018
Fallopian Tube Cancer - Pipeline by Pfizer Inc, H1 2018
Fallopian Tube Cancer - Pipeline by Pharma Mar SA, H1 2018

List of Figures
Number of Products under Development for Fallopian Tube Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs